Reports Q1 revenue $317.0M, consensus $310.6M. “Our 2025 momentum continued in the first quarter as we delivered revenue and adjusted earnings ahead of our expectations,” said Patrick J. Beyer, CONMED’s (CNMD) President and Chief Executive Officer. “We continue to concentrate our resources and investment on our higher-growth, higher-margin areas: minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNMD:
- CNMD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Conmed assumed with an Equal Weight at Wells Fargo
- DraftKings, Eli Lilly downgraded: Wall Street’s top analyst calls
- Maintaining a Neutral Stance Amid Persistent AirSeal Headwinds and Execution Challenges
- Conmed downgraded to Neutral from Overweight at Piper Sandler